Brief

CEO of Nasdaq-Listed Cell Immunotherapy Company Enlivex Steps Down

Enlivex develops cell-based treatments for life-threatening immune and inflammatory conditions, such as graft versus host disease, a post bone marrow transplant complication

Schmuel Hess, the CEO of Jerusalem-based immunotherapy company Enlivex Therapeutics Ltd. is set to step down in December due to personal reasons, the company announced in a filing to the U.S. Securities and Exchange Commission (SEC) earlier this week. The company, dually listed on Nasdaq and the Tel Aviv Stock Exchange, announced that pending selection of a new CEO, the company intends to appoint Dror Mevorach, the company’s founder and chief scientific officer, as interim CEO.

 

Founded in 2005, clinical-stage Enlivex develops cell-based treatments for life-threatening immune and inflammatory conditions, such as graft versus host disease, a post bone marrow transplant complication.

Enlivex chairman Shai Novik. Photo: Amit Sha'al